GeoVax's Cash Dwindles to $1.3M Amid $5.3M Q1 Loss, Raising Going Concern Fears
GOVX sits 31% above its 52-week low of $0.963.
Summary
GeoVax Labs reported a net loss of $5.3 million for Q1 2026, with cash and cash equivalents plummeting to just $1.3 million as of March 31, 2026. This critical cash position, down from $3.086 million at year-end, confirms the 'going concern' warning highlighted in the company's recent 10-K, which projected a cash runway only into mid-Q2 2026. The company also reported $0 revenue from government contracts, a significant drop from $1.6 million in Q1 2025, following a BARDA contract termination. While GeoVax is advancing its GEO-MVA vaccine program into Phase 3, the severe financial distress and rapid cash burn rate for a company with a ~$3.6 million market cap indicate an urgent need for substantial capital, likely through highly dilutive financing. Traders will be closely watching for immediate capital raise announcements or further deterioration of the cash position.
At the time of this announcement, GOVX was trading at $1.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $0.96 to $34.75. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.